Life Sciences
Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.
The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.
We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies.
Explore our sectors
Meet our lawyers
News and insights
Publications: 20 March 2023
Abuse of dominance enforcement paves path for digital reform
2022 saw a significant decrease in fines across the world for abuse of dominance cases. Authorities continued to focus on ‘Big Tech’, but were more willing to accept commitments from firms in place of…
Blog Post: 08 March 2023
Tine Carmeliet, Juno Hautekiet and Geert Glas discuss how early-stage life sciences companies can survive the so-called “valley of death”. This is the funding gap between making a promising scientific…
Publications: 23 February 2023
Scrutiny of tech deals remains a priority with PE and labour markets in the spotlight
Digital/tech transactions remain high on the enforcement agenda. Last year brought high-profile tech cases and progression of new digital rules. Overall, however, antitrust intervention focused on…
Publications: 16 February 2023
Sanctions in the spotlight: the High Court considers Russia sanctions implications
The High Court in London has issued a number of judgments in recent weeks that consider the implications of the sanctions that have been imposed on Russia in the last 12 months. In this article, we…
Recognition
I have used Allen & Overy for coordinating EU cases. They have extensive knowledge of coordinating litigation.
Clients quoted in Chambers Global 2021 (Life Sciences: Global-wide)
They are well equipped to explain and navigate the different local jurisdictions to help towards a better understanding of various markets.
Client quoted in Chambers Europe 2021 (Intellectual Property: Europe-wide)
Strong European offering with noted expertise in IP and patent litigation matters. Well regarded for its impressive client portfolio, which spans the pharmaceutical, biotechechnology, medtech, diagnostics and healthcare industries. Also offers impressive expertise in commercial transactions and M&A.
Chambers Global 2018 (Life Sciences: Global-wide)
Related links
Life Sciences Hub
We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.
Read moreCRISPR microsite
The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.
Go to micrositeGrowth Capital microsite
Allen & Overy is an engaged and active player in the growth company ecosystem.
Go to micrositeRelated content
Global trends in merger control enforcement
Record levels in the first half of 2018 and considerable contraction in the second.